VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ZLAB
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ZLABZai Lab Limited
$25.48$2.9B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksZLABCash Flow

Zai Lab Limited (ZLAB) Cash Flow Statement

11Y historyFree accessUpdated daily

Free cash flow improved from -$103.1M in 2024Q1 to -$46.8M in 2026Q2 but remains deeply negative, with OCF/NI averaging 0.76 and cumulative net losses of -$534.5M outpacing operating cash burn of -$403.0M over ten quarters.

Income StatementBalance SheetCash FlowRatios

ZLAB Cash Flow Statement

Annual statement

ZLAB Cash Flow Statement

Zai Lab Limited (ZLAB) cash flow statement — 11-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15
Cash from Operations-159.21M-150.79M-214.87M-198.18M-367.64M-549.23M-216.06M-191.01M-97.54M-32.37M-32.16M-11.46M
Operating CF Margin %--32.77%-53.85%-74.3%-170.96%-380.59%-441.31%-1471.04%-75346.86%---
Operating CF Growth %-50.93%29.82%-8.42%46.09%33.06%-154.21%-13.11%-95.83%-201.35%-0.65%-180.49%-
Net Income-198.39M-175.54M-257.1M-334.62M-443.29M-704.47M-268.9M-195.07M-139.07M-50.38M-37.51M-18.02M
Depreciation & Amortization16.44M15.01M11.86M9.03M8.23M6.49M4.64M3.77M1.65M548K199K126.51K
Stock-Based Compensation52.37M65.6M70.65M79.63M61.3M40.71M24.83M20.29M12.23M9.93M4.93M2.7M
Deferred Taxes-2.94M000017.08M1.13M767K587.25K000
Other Non-Cash Items-21.03M-1.15M28.12M8.17M72.36M67.85M4.01M2.52M-312K62.74K1.92M2.02M
Working Capital Changes-5.66M-54.71M-68.39M39.61M-66.25M23.11M18.25M-23.28M27.38M7.48M-1.69M1.71M
Change in Receivables28.04M-29.98M-26.58M-17.69M25.14M-42.32M-1.38M-3.7M-89.71K000
Change in Inventory-39.08M-47.03M3.9M-14.91M-15.38M-7.17M-7.17M-6M-3.82K000
Change in Payables17.14M19.93M-2.21M36.8M-53.77M63.52M39.98M-14.77M28.46M8.44M-929.72K1.29M
Cash from Investing-47.68M307.87M-375.19M-10.78M420.02M249.96M-554.83M-14.89M-212.55M-10.43M-2.73M-738.47K
Capital Expenditures-4.13M-8.1M-5.66M-7.21M-24.59M-18.95M-10.67M-15.24M-10.12M-9.12M-2.23M-738.47K
CapEx % of Revenue0.93%1.76%1.42%2.7%11.43%13.13%21.79%117.38%7815.9%---
Acquisitions0029K00-30M539K9.21M-2.09M-1.9M00
Investments------------
Other Investing-43.55M-5.24M-55.86M12.74M-399K3K-539K-9.21M-102.83K68.1K-505.62K0
Cash from Financing37.9M72.35M349.89M-6.43M-1.73M820.2M1.13B219.3M144.15M187.86M106.2M18.28M
Debt Issued (Net)37.82M67.94M131.32M000-6.53M2.9M3.64M000
Equity Issued (Net)4.78M13.68M217.35M00818.88M1.14B216.2M141M189.53M106.2M18.28M
Dividends Paid000000000000
Share Repurchases000000000000
Other Financing-4.7M-9.27M1.22M-6.43M-1.73M1.33M1.28M201K-496.2K-1.67M00
Net Change in Cash-167.49M229.91M-240.48M-218.01M44.37M522.04M366.42M13.49M-166.71M145.71M70.79M6.01M
Free Cash Flow-163.96M-164.21M-276.39M-206.67M-392.63M-568.18M-226.72M-206.25M-107.66M-41.48M-34.39M-12.2M
FCF Margin %-37.12%-35.69%-69.27%-77.49%-182.58%-393.72%-463.1%-1588.42%-83162.76%---
FCF Growth %20.72%40.59%-33.74%47.36%30.9%-150.6%-9.93%-91.59%-159.51%-20.64%-181.79%-
FCF per Share-1.46-1.50-2.79-21.39-40.98-61.10-29.19-32.04-20.46-19.07-36.43-14.04
FCF Conversion (FCF/Net Income)0.83x0.86x0.84x0.59x0.83x0.78x0.80x0.98x0.70x0.64x0.86x0.64x
Interest Paid454K4.88M2.02M000000000
Taxes Paid000000000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Persistent operating losses

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Cash Conversion Remains Elusive

Zai Lab's operating cash flow has consistently underperformed net losses, with OCF/NI averaging 0.76 over the past ten quarters, indicating persistent negative accruals and weak earnings quality.

The gap between net income and operating cash flow is stark: in 2026Q1, OCF was -$11.9M versus a net loss of -$51.0M, a ratio of 0.23, suggesting that non-cash charges like SBC and D&A are masking a deeper cash burn. However, in 2025Q1, OCF exceeded net loss (ratio 1.27), driven by a large working capital outflow, highlighting volatility in cash conversion. This inconsistency suggests that reported losses do not fully capture the cash drain, and investors should monitor the sustainability of working capital swings.

FCF Burn Persists Despite Narrowing

Free cash flow has improved from -$103.1M in 2024Q1 to -$46.8M in 2026Q2, but remains deeply negative, with FCF margins improving from -118.3% to -44.1% over the same period.

The trajectory shows a gradual narrowing of FCF burn, but the improvement is not linear; 2025Q1 saw a spike to -$65.6M, and 2026Q1 improved to -$34.2M before widening again. This suggests that cost controls are having some effect, but the company is still far from cash flow breakeven. Given the prior income statement analysis showing decelerating revenue growth, the FCF improvement may be driven by working capital timing rather than operational leverage, warranting caution.

Minimal Capex Signals Asset-Light Model

Capital expenditures have averaged just 1.4% of revenue over the past ten quarters, totaling roughly $16M, indicating a highly asset-light model with limited need for fixed asset investment.

With CapEx/Revenue consistently below 3%, Zai Lab's cash burn is almost entirely operational, not capital-intensive. This suggests that the company's investments are primarily in R&D and commercialization rather than physical assets, which may be typical for a biotech. However, the low capex also implies that future growth may require significant external funding for manufacturing or infrastructure, which is not yet reflected in the cash flow statement.

Working Capital Swings Drive Cash Volatility

Working capital changes have swung from -$57.2M in 2024Q1 to +$35.9M in 2026Q1, creating significant quarter-to-quarter volatility in operating cash flow, as reported in quarterly filings.

The working capital line is the primary driver of OCF volatility, with large outflows in 2024Q1, 2025Q1, and 2025Q3, and inflows in 2026Q1. This pattern suggests that Zai Lab's cash flow is heavily influenced by timing of receivables, payables, and inventory, which may not reflect underlying operational performance. Investors should monitor whether these swings indicate improving efficiency or simply timing mismatches, as the company continues to burn cash.

No Capital Returns, All Cash to Operations

Zai Lab has paid no dividends and repurchased only $2.2M in shares in 2026Q2, with no acquisition activity, indicating that all available cash is being consumed by operating losses.

The absence of dividends and minimal buybacks underscores that the company is in a preservation mode, with cash reserves being used to fund ongoing losses. The $2.2M buyback in 2026Q2 is negligible relative to the quarterly burn, suggesting it may be opportunistic rather than a strategic return of capital. This deployment strategy is consistent with a company that needs to conserve cash to extend its runway, but it also means shareholders are not receiving any direct returns.

Cumulative Losses Outpace Cash Burn

Over the past ten quarters, cumulative net losses totaled -$534.5M while operating cash flow was -$403.0M, a $131.5M divergence that suggests non-cash charges are inflating reported losses.

The cumulative gap between net income and operating cash flow indicates that a significant portion of reported losses are non-cash, primarily SBC and D&A, which totaled approximately $150M over the period. This divergence implies that the actual cash burn is lower than the accounting losses, but still substantial. However, the gap is not consistent, and the company's cash position may be deteriorating faster than the income statement suggests, given the working capital outflows. This warrants close monitoring of the balance sheet.

What Could Invalidate the Base Case

The cash flow statement may obscure the true cash position due to significant stock-based compensation and working capital timing, potentially understating the urgency of funding needs.

While SBC and D&A are non-cash, they represent real dilution and asset consumption that are not captured in operating cash flow. The large working capital swings could be masking a more stable underlying burn, and the absence of capex may understate future capital needs if the company scales manufacturing. Investors should consider that the reported cash burn may not fully reflect the economic cost of operations, and the company may need to raise capital sooner than the cash flow statement alone suggests.

ZLAB — Frequently Asked Questions

Quick answers to the most common questions about buying ZLAB stock.

How much cash does Zai Lab Limited (ZLAB) generate from operations?

Zai Lab Limited (ZLAB) generated $-150.8M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Zai Lab Limited's free cash flow?

Zai Lab Limited (ZLAB) reported negative free cash flow of $164.2M in 2025, indicating capital requirements exceeded cash from operations.

What is Zai Lab Limited's capital expenditure (CapEx)?

Zai Lab Limited (ZLAB) spent $8.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.